Hepatic progenitors and strategies for liver cell therapies.
Hepatic progenitors and strategies for liver cell therapies.
复制标题
肝祖细胞和肝细胞治疗策略。
DOI：
10.1111/j.1749-6632.2001.tb03851.x
复制
发表时间：
2001
影响因子：
5.2
通讯作者：
Reid,LM
中科院分区：
文献类型：
--
作者：
Susick,R;Moss,N;Kubota,H;Lecluyse,E;Hamilton,G;Luntz,T;Ludlow,J;Fair,J;Gerber,D;Bergstrand,K;White,J;Bruce,A;Drury,O;Gupta,S;Reid,LM
翻译后摘要：肝细胞疗法，包括肝细胞移植和生物人工肝，正在开发的替代全肝移植的一些严重肝功能障碍的患者。肝祖细胞被认为是用于这些肝细胞疗法的理想细胞，因为它们具有广泛扩增、分化成所有成熟肝细胞、具有最小免疫原性、可冷冻保存以及在移植时重建肝组织的能力。我们总结了我们正在进行的努力，以开发肝祖细胞治疗的临床计划，重点是肝干细胞生物学和策略，已经出现在分析生物学。
Abstract:Liver cell therapies, including liver cell transplantation and bioartificial livers, are being developed as alternatives to whole liver transplantation for some patients with severe liver dysfunction. Hepatic progenitors are proposed as ideal cells for use in these liver cell therapies given their ability to expand extensively, differentiate into all mature liver cells, have minimal immunogenicity, be cryopreservable, and reconstitute liver tissue when transplanted. We summarize our ongoing efforts to develop clinical programs of hepatic progenitor cell therapies with a focus on hepatic stem cell biology and strategies that have emerged in analyzing that biology.